MRNA COVID-19 Vaccination During Pregnancy Unlinked to Autism or Developmental Disorders, Major Study Confirms

Receiving an mRNA COVID-19 vaccine shortly before or at any point during pregnancy is not linked to autism or other developmental disorders in children, according to groundbreaking research presented at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting. These definitive findings offer crucial new data on the long-term health trajectories of children whose mothers were vaccinated around the time of conception or during their gestational period, providing significant reassurance to expectant parents and healthcare providers worldwide.

The Genesis of Concern: Navigating Pandemic Uncertainty

The advent of the COVID-19 pandemic in early 2020 unleashed an unprecedented global health crisis, prompting an urgent, accelerated effort to develop effective vaccines. By late 2020 and early 2021, the first messenger ribonucleic acid (mRNA) vaccines, such as those produced by Pfizer-BioNTech and Moderna, received emergency use authorization and began to be rolled out globally. These vaccines, along with protein subunit vaccines, represented a monumental scientific achievement in combating the novel coronavirus. However, their rapid development, coupled with a dearth of initial data specifically on pregnant individuals, sparked considerable public concern and vaccine hesitancy within this vulnerable population.

Pregnant people were initially excluded from primary vaccine trials, a standard practice in pharmaceutical research due to ethical considerations regarding potential fetal exposure. This exclusion, while ethically grounded, inadvertently created a vacuum of specific data for a group known to be at higher risk for severe COVID-19 outcomes, including increased rates of intensive care unit admission, mechanical ventilation, and even death, compared to non-pregnant individuals of reproductive age. Furthermore, COVID-19 infection during pregnancy was associated with adverse perinatal outcomes such as preterm birth, preeclampsia, and stillbirth. The absence of robust, pregnancy-specific data led to widespread questions and anxieties about vaccine safety for both the mother and the developing fetus, particularly concerning potential long-term neurodevelopmental effects in children. Misinformation and unsubstantiated claims, often circulated through social media, further exacerbated these fears, leading many pregnant individuals to decline vaccination despite mounting evidence of its safety and efficacy from observational studies and real-world data.

Public health organizations, including the U.S. Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and the World Health Organization (WHO), progressively updated their recommendations as more data emerged, ultimately strongly advocating for COVID-19 vaccination at any stage of pregnancy. These recommendations were based on accumulating evidence demonstrating vaccine safety regarding maternal health and immediate birth outcomes, such as rates of miscarriage, stillbirth, and preterm delivery. However, a critical gap remained concerning the very long-term health of children, specifically addressing concerns about neurodevelopmental disorders like autism, which often manifest and are diagnosed later in early childhood. The research presented at the SMFM 2026 Pregnancy Meeting directly addresses this significant gap, offering a robust, prospective assessment of these long-term outcomes.

A Landmark Investigation: The Study Design and Scope

The investigation, spearheaded by researchers within the esteemed Maternal-Fetal Medicine Units (MFMU) Network, represents a cornerstone in understanding the long-term effects of maternal COVID-19 vaccination. The MFMU Network, supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is a consortium of clinical centers across the United States dedicated to conducting high-quality research on maternal and fetal health, known for its rigorous scientific standards and large-scale studies. This particular study was designed as a prospective, multi-center, and observational investigation, a methodology chosen to track outcomes in real-time across diverse clinical settings and populations, thereby enhancing the generalizability and robustness of its findings.

The study period spanned from May 2024 to March 2025, during which researchers meticulously evaluated a cohort of 434 children. These children ranged in age from 18 months to 30 months, an age window critical for the initial identification of signs associated with autism spectrum disorder (ASD) and other pervasive developmental concerns. The cohort was evenly divided into two groups: 217 children born to mothers who had received at least one dose of an mRNA COVID-19 vaccine either during pregnancy or within 30 days prior to becoming pregnant, and a control group of 217 children whose mothers did not receive an mRNA vaccine during or immediately preceding pregnancy. This careful stratification allowed for a direct comparison of developmental trajectories between vaccinated and unvaccinated groups.

Rigorous Methodology and Participant Matching

To ensure the comparison was as accurate and unbiased as possible, the research team implemented a meticulous matching protocol. Vaccinated mothers were paired with unvaccinated mothers based on several key demographic and clinical factors that could potentially influence child development or maternal health outcomes. These factors included the location of delivery (e.g., hospital, birth center), the exact date of delivery to account for temporal trends, insurance status as an indicator of socioeconomic factors and access to care, and self-reported race. This stringent matching process aimed to minimize confounding variables, ensuring that any observed differences or, in this case, the lack thereof, could be more confidently attributed to vaccine exposure rather than other socio-economic or healthcare access disparities.

Furthermore, the study applied strict exclusion criteria for both groups to enhance the homogeneity of the cohorts and focus on healthy, full-term singleton pregnancies. Excluded from the study were pregnancies that ended before 37 weeks of gestation (preterm births), those involving multiple babies (twins, triplets, etc., which often have different developmental trajectories), or those that resulted in a child diagnosed with a major congenital malformation. By excluding these factors, the researchers aimed to isolate the potential effects of the vaccine on neurodevelopment, removing other known significant contributors to developmental variations.

Unveiling the Findings: No Observable Differences

The core finding of the study was unequivocal and highly reassuring. "Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine," stated Dr. George R. Saade, MD, a senior researcher on the project. Dr. Saade, who is also Professor and Chair of Obstetrics and Gynecology and Associate Dean for Women’s Health at Macon & Joan Brock Virginia Health Sciences at Old Dominion University in Norfolk, VA, underscored the consistency of findings across all assessed developmental domains. This statement directly addresses and refutes the widespread concerns that maternal COVID-19 vaccination might negatively impact a child’s brain development, leading to conditions like autism or other delays.

Comprehensive Developmental Assessments

To arrive at these conclusions, researchers employed a multi-faceted approach to assess the children’s development when they reached 1.5 to 2.5 years of age. The primary screening tool utilized was the Ages and Stages Questionnaire Version 3 (ASQ-3). The ASQ-3 is a widely validated, parent-completed developmental screening tool that measures progress in five crucial areas of early childhood development:

1. Communication: Including babbling, gestures, and understanding of language.
2. Gross Motor Skills: Such as sitting, crawling, walking, and running.
3. Fine Motor Skills: Involving hand and finger movements, like grasping objects and drawing.
4. Problem Solving: Including curiosity, exploration, and the ability to solve simple tasks.
5. Personal Social Interaction: Measuring self-help skills and interactions with others.
   A score indicating a concern in any of these areas would prompt further investigation.

Beyond the ASQ-3, the research team also reviewed results from several other standardized and respected assessment tools to provide a comprehensive picture of each child’s behavioral and developmental patterns. These included:

• The Child Behavior Checklist (CBCL): A questionnaire completed by parents or caregivers to assess emotional, behavioral, and social problems in children.
• The Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT-R/F): A screening tool specifically designed to identify young children at risk for autism spectrum disorder.
• The Early Childhood Behavior Questionnaire (ECBQ): Which assesses temperament dimensions in infants and toddlers, such as activity level, positive affect, and fear.
  The consistent findings across these diverse and robust assessment instruments further strengthen the study’s conclusions, demonstrating no statistically significant differences in developmental outcomes, including autism risk, between the two groups.

Expert Perspectives and Reassurance

The findings were met with significant positive reception within the maternal-fetal medicine community. Dr. Brenna L. Hughes, MD, MSc, the Edwin Crowell Hamblen Distinguished Professor of Reproductive Biology and Family Planning and Interim Chair of the Department of Obstetrics and Gynecology at Duke University in Raleigh, NC, emphasized the rigorous nature of the study. "This study, conducted through a rigorous scientific process in an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy," Dr. Hughes remarked. Her statement highlights not only the positive outcome but also the credibility derived from the study’s adherence to stringent scientific protocols and its affiliation with a prestigious NIH-funded network.

These expert endorsements are crucial for translating research into clinical practice and public health messaging. The MFMU Network’s involvement lends significant weight, as its studies are known for their methodological rigor and their impact on clinical guidelines. The consistent recommendations from leading professional organizations like ACOG and SMFM for vaccination during pregnancy are now further solidified by this long-term developmental data. This provides healthcare providers, from obstetricians and family physicians to pediatricians, with an even stronger evidence base to counsel their patients confidently.

A Chronology of Data and Discovery

The journey from pandemic onset to these definitive long-term findings spans several years, illustrating the meticulous and patient process of scientific inquiry:

• Early 2020: COVID-19 pandemic declared, rapid global spread.
• Late 2020 – Early 2021: mRNA COVID-19 vaccines receive Emergency Use Authorization; initial vaccination campaigns begin. Pregnant individuals largely excluded from initial trials, leading to data gaps.
• Mid-2021 onwards: Observational studies and real-world data begin to accumulate, suggesting safety of COVID-19 vaccination in pregnancy regarding maternal health and immediate birth outcomes. Public health organizations (CDC, ACOG, WHO) recommend vaccination for pregnant individuals.
• May 2024: The Maternal-Fetal Medicine Units Network study commences, prospectively enrolling pregnant individuals and planning for long-term follow-up of their children. This marks the start of addressing the critical long-term neurodevelopmental question.
• March 2025: Data collection for the children’s developmental assessments concludes, capturing outcomes at 18-30 months of age.
• February 2026: The research findings are formally presented at the SMFM 2026 Pregnancy Meeting.
• February 2026: The oral abstract #8, titled "Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," is published in PREGNANCY, the official peer-reviewed medical journal of the Society for Maternal-Fetal Medicine.

This timeline underscores the commitment to evidence-based medicine, moving from initial emergency response to comprehensive, long-term follow-up studies designed to address specific public health concerns with scientific precision.

Broader Implications for Public Health and Parental Confidence

The implications of this study are far-reaching, extending beyond clinical practice to public health policy and the profound psychological impact on parents. In an era rife with health misinformation, these findings serve as a powerful counter-narrative to unsubstantiated claims linking vaccines to autism—a false premise that has unfortunately persisted for decades despite overwhelming scientific debunking. The explicit scientific evidence that mRNA COVID-19 vaccination during pregnancy does not increase the risk of autism or other developmental disorders is invaluable in combating vaccine hesitancy and building trust in medical science.

Combating Vaccine Hesitancy with Evidence

For current and future expectant parents, this study offers immense reassurance. The decision to vaccinate during pregnancy often involves balancing perceived risks and benefits, and the lack of long-term data on offspring neurodevelopment has been a significant point of concern for many. With this study, parents can make informed decisions based on robust, peer-reviewed scientific evidence, confident that protecting themselves from severe COVID-19 via vaccination will not compromise their child’s long-term developmental health. This newfound clarity can empower parents to prioritize their health and the health of their babies without undue anxiety, potentially leading to higher vaccination rates among pregnant populations and, consequently, reduced maternal and infant morbidity and mortality associated with COVID-19.

The Path Forward: Sustained Surveillance and Research

While this study provides critical long-term data up to 30 months of age, the scientific community recognizes the importance of sustained surveillance. Future research might explore even longer-term follow-up into school-age years, investigate potential nuances with different vaccine platforms (though mRNA and protein subunit vaccines are generally considered safe), or delve into specific populations with unique risk factors. However, the current findings offer a substantial foundation, confirming the safety profile of mRNA COVID-19 vaccines in pregnancy regarding early childhood neurodevelopment. The study also reinforces the broader understanding that vaccines, developed through rigorous scientific processes, are crucial tools for public health, particularly for vulnerable populations like pregnant individuals and their offspring.

Funding and Scientific Integrity

The study’s integrity is further bolstered by its funding source: the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health (NIH). This federal funding signifies a commitment to public health and independent scientific inquiry. The authors responsibly noted that the conclusions presented are their own and do not necessarily reflect the official views of the National Institutes of Health, a standard practice that underscores scientific autonomy and objectivity in research dissemination. This transparency reinforces the credibility of the findings and the dedication to unbiased research.

In conclusion, the research presented at the SMFM 2026 Pregnancy Meeting represents a pivotal moment in understanding the comprehensive safety profile of mRNA COVID-19 vaccination during pregnancy. By definitively demonstrating no link to autism or other developmental disorders in toddlers, this study not only provides profound reassurance to families and healthcare providers but also serves as a critical evidence-based tool in the ongoing global effort to promote vaccine confidence and safeguard public health.